Concise review: Mesenchymal stem cell treatment for ischemic kidney disease

Stem Cells

Volumn 31, Issue 9, 2013, Pages 1731-1736

  Zhu, Xiang Yang ^a   Lerman, Amir ^a   Lerman, Lilach O ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cellular therapy; Inflammation; Kidney; Mesenchymal stem cells

Indexed keywords

HORMONE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INTERACTION; CHRONIC ISCHEMIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE; ENDOCRINE SYSTEM; ENGRAFTMENT; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY ISCHEMIA; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PARACRINE SIGNALING; PATHOPHYSIOLOGY; RENAL PROTECTION;

CELLULAR THERAPY; INFLAMMATION; KIDNEY; MESENCHYMAL STEM CELLS;

ACUTE KIDNEY INJURY; HUMANS; ISCHEMIA; KIDNEY DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84885124786     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1449     Document Type: Article

References (42)

1. van Ampting JM, Penne EL, Beek FJ, et al. Prevalence of atherosclerotic renal artery stenosis in patients starting dialysis. Nephrol Dial Transplant 2003; 18: 1147-1151.
2. Fatica RA, Port FK, Young EW,. Incidence trends and mortality in end-stage renal disease attributed to renovascular disease in the United States. Am J Kidney Dis 2001; 37: 1184-1190.
3. Morigi M, Introna M, Imberti B, et al. Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells 2008; 26: 2075-2082.
4. Togel F, Cohen A, Zhang P, et al. Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cells Dev 2009; 18: 475-485.
5. Ninichuk V, Gross O, Segerer S, et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int 2006; 70: 121-129.
6. Semedo P, Correa-Costa M, Antonio Cenedeze M, et al. Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model. Stem Cells 2009; 27: 3063-3073.
7. Bianco P, Cao X, Frenette PS, et al. The meaning, the sense and the significance: Translating the science of mesenchymal stem cells into medicine. Nat Med 2013; 19: 35-42.
8. Eltzschig HK, Eckle T,. Ischemia and reperfusion-From mechanism to translation. Nat Med 2011; 17: 1391-1401.
9. Cantaluppi V, Biancone L, Quercia A, et al. Rationale of mesenchymal stem cell therapy in kidney injury. Am J Kidney Dis 2013; 61: 300-309.
10. Zhu XY, Urbieta-Caceres V, Krier JD, et al. Mesenchymal stem cells and endothelial progenitor cells decrease renal injury in experimental swine renal artery stenosis through different mechanisms. Stem Cells 2013; 31: 117-125.
11. Hara Y, Stolk M, Ringe J, et al. In vivo effect of bone marrow-derived mesenchymal stem cells in a rat kidney transplantation model with prolonged cold ischemia. Transpl Int 2011; 24: 1112-1123.
12. Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: A randomized controlled trial. JAMA 2012; 307: 1169-1177.
13. Chang CL, Leu S, Sung HC, et al. Impact of apoptotic adipose-derived mesenchymal stem cells on attenuating organ damage and reducing mortality in Rat sepsis syndrome induced by cecal puncture and ligation. J Transl Med 2012; 10: 244.
14. Yagi H, Soto-Gutierrez A, Kitagawa Y, et al. Bone marrow mesenchymal stromal cells attenuate organ injury induced by LPS and burn. Cell Transplant 2010; 19: 823-830.
15. Kim JH, Park DJ, Yun JC, et al. Human adipose tissue-derived mesenchymal stem cells protect kidneys from cisplatin nephrotoxicity in rats. Am J Physiol Renal Physiol 2012; 302: F1141-1150.
16. Westenfelder C, Togel FE,. Protective actions of administrated mesenchymal stem cells in acute kidney injury: Relevance to clinical trials. Kidney Int Suppl 2011; 1: 103-106.
17. Zhu XY, Chade AR, Krier JD, et al. The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension. J Hypertens 2009; 27: 2063-2073.
18. Zhu XY, Chade AR, Rodriguez-Porcel M, et al. Cortical microvascular remodeling in the stenotic kidney: Role of increased oxidative stress. Arterioscler Thromb Vasc Biol 2004; 24: 1854-1859.
19. Liu H, Liu S, Li Y, et al. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. Plos One 2012; 7: e34608.
20. Herrera MB, Bussolati B, Bruno S, et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int 2007; 72: 430-441.
21. Togel F, Isaac J, Hu Z, et al. Renal SDF-1 signals mobilization and homing of CXCR4-positive cells to the kidney after ischemic injury. Kidney Int 2005; 67: 1772-1784.
22. Bruno S, Grange C, Deregibus MC, et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 2009; 20: 1053-1067.
23. Gatti S, Bruno S, Deregibus MC, et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant 2011; 26: 1474-1483.
24. Hagiwara M, Shen B, Chao L, et al. Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum Gene Ther 2008; 19: 807-819.
25. Humphreys BD, Czerniak S, DiRocco DP, et al. Repair of injured proximal tubule does not involve specialized progenitors. Proc Natl Acad Sci USA 2011; 108: 9226-9231.
26. Humphreys BD, Valerius MT, Kobayashi A, et al. Intrinsic epithelial cells repair the kidney after injury. Cell Stem Cell 2008; 2: 284-291.
27. Lin F, Moran A, Igarashi P,. Intrarenal cells, not bone marrow-derived cells, are the major source for regeneration in postischemic kidney. J Clin Invest 2005; 115: 1756-1764.
28. Togel F, Weiss K, Yang Y, et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 2007; 292: F1626-1635.
29. Morigi M, Imberti B, Zoja C, et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004; 15: 1794-1804.
30. Chade AR, Zhu X, Lavi R, et al. Endothelial progenitor cells restore renal function in chronic experimental renovascular disease. Circulation 2009; 119: 547-557.
31. Wheatley K, Ives N, Gray R, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009; 361: 1953-1962.
32. Eirin A, Zhu XY, Krier JD, et al. Adipose tissue-derived mesenchymal stem cells improve revascularization outcomes to restore renal function in swine atherosclerotic renal artery stenosis. Stem Cells 2012; 30: 1030-1041.
33. Fang Y, Tian X, Bai S, et al. Autologous transplantation of adipose-derived mesenchymal stem cells ameliorates streptozotocin-induced diabetic nephropathy in rats by inhibiting oxidative stress, pro-inflammatory cytokines and the p38 MAPK signaling pathway. Int J Mol Med 2012; 30: 85-92.
34. Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003; 101: 2999-3001.
35. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect. Stem Cells Dev 2009; 18: 683-692.
36. Zonta S, De Martino M, Bedino G, et al. Which is the most suitable and effective route of administration for mesenchymal stem cell-based immunomodulation therapy in experimental kidney transplantation: Endovenous or arterial? Transplant Proc 2010; 42: 1336-1340.
37. Zhuo W, Liao L, Fu Y, et al. Efficiency of endovenous versus arterial administration of mesenchymal stem cells for ischemia-reperfusion-induced renal dysfunction in rats. Transplant Proc 2013; 45: 503-510.
38. Alfarano C, Roubeix C, Chaaya R, et al. Intraparenchymal injection of bone marrow mesenchymal stem cells reduces kidney fibrosis after ischemia-reperfusion in cyclosporine-immunosuppressed rats. Cell Transplant 2012; 21: 2009-2019.
39. Thirabanjasak D, Tantiwongse K, Thorner PS,. Angiomyeloproliferative lesions following autologous stem cell therapy. J Am Soc Nephrol 2010; 21: 1218-1222.
40. van Koppen A, Joles JA, van Balkom BW, et al. Human embryonic mesenchymal stem cell-derived conditioned medium rescues kidney function in rats with established chronic kidney disease. Plos One 2012; 7: e38746.
41. Reis LA, Borges FT, Simoes MJ, et al. Bone marrow-derived mesenchymal stem cells repaired but did not prevent gentamicin-induced acute kidney injury through paracrine effects in rats. Plos One 2012; 7: e44092.
42. Lee SR, Lee SH, Moon JY, et al. Repeated administration of bone marrow-derived mesenchymal stem cells improved the protective effects on a remnant kidney model. Ren Fail 2010; 32: 840-848.